Company / SG&A Expense
Travere Therapeutics, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$337.2M
FY2025
5-year range
$129.0M / $337.2M
FY2021-FY2025
Trend
+27.7%
vs FY2024
Sector context
#52 of 213
Health Care
What the data says
Travere Therapeutics, Inc.'s sg&a expense of $337M is higher than 76% of companies in the Health Care sector (FY2025). Increased from $266M to $337M over the past 2 years.
Based on SEC 10-K filings.
$337M in FY2025 with a 5-year CAGR of +26.6%. Top quartile in the Health Care sector.
Increased from $266M to $337M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +19.5%
- 5-Year CAGR
- +26.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 24% in Health CareTop 76% of 213This company $337.2M Sector average $722.3M
▼
-53.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +26.6%, indicating consistent growth.
- In FY2025, sg&a expense increased 27.7% year-over-year.
- Ranks #52 out of 213 companies in the Health Care sector.
- Lowest sg&a expense in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $337.2M | +27.7% |
| FY2024 | $264.1M | -0.5% |
| FY2023 | $265.5M | +34.4% |
| FY2022 | $197.5M | +53.2% |
| FY2021 | $129.0M | +24.4% |
| FY2020 | $103.7M | +2.3% |
| FY2019 | $101.3M | +10.2% |
| FY2018 | $91.9M | +15.6% |
| FY2017 | $79.5M | +33.4% |
| FY2016 | $59.6M | -25.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026